Assessing Airway Resistance Using Plethysmography as Lung Function Testing Among Asymptomatic Rheumatoid Arthritis Patients.

Pulmonary events in rheumatoid arthritis (RA) reflects the involvement of pleurae, lung interstitium, and airways. Overall, pulmonary manifestations are estimated to cause 10–20% of mortalities in RA. Respiratory system involvement as extra-articular presentations of RA is common among some Saudi patients. This study aims to evaluate specific airway conductance (sGaw), airway resistance (Raw), and specific airway resistance (sRaw), using plethysmography. Comparison for deployed methods is made by forced spirometer as an indicator for obstruction among patients with RA. The study sought to use the methods to enhance lung testing among RA patients. An analytical, hospital-based study was carried out at pulmonary function test laboratory, department of respiratory care King Saud Medical City (KSMC). RA patients were selected, with an age group of 18-75years. The tests for Forced spirometer and plethysmography were carried out to assess and analyze how the respiratory mechanism was impacted by the disease. Data collected was analyzed using Statistical Package for Social Sciences (SPSS), version 21. The obstructive and mixed ventilation patterns constituted 15%; the mean values of Raw and sRaw were significantly higher compared to mean values predicted for participants selected during the study, while sGaw was significantly lower compared to mean values predicted for participants selected. Monitoring of airway resistance parameters using plethysmography can be used as indicators of lung function testing among RA patients.

Download Full-text

Lung function testing

Current Paediatrics ◽

10.1016/s0957-5839(05)80051-x ◽

1993 ◽

Vol 3 (2) ◽

pp. 92-95

Author(s):

P. Helms

Keyword(s):

Lung Function ◽

Lung Function Testing ◽

Function Testing

Download Full-text

Pulmonary Manifestations of Rheumatoid Arthritis

The Senior Care Pharmacist ◽

10.4140/tcp.n.2021.97 ◽

2021 ◽

Vol 36 (2) ◽

pp. 97-103

Author(s):

Keith J. Christensen ◽

Mark A. Malesker ◽

Nikhil Jagan ◽

Douglas R Moore

Keyword(s):

Rheumatoid Arthritis ◽

Needle Biopsy ◽

Pulmonary Toxicity ◽

Pharmacy Practice ◽

Pulmonary Function Testing ◽

Therapeutic Outcomes ◽

Pulmonary Manifestations ◽

Lost To Follow Up ◽

Function Testing

Objective To describe the case of an 88-year-old male with rheumatoid arthritis who developed pulmonary manifestations. Treatment for his RA previously included various biologics, while at the time of pulmonary consultation included meloxicam, methotrexate, and abatacept. Following chest scans, bronchoscopy, needle biopsy, pulmonary function testing, and a thoracentesis, the diagnosis of pleural effusion and nodules associated with rheumatoid arthritis was determined. The patient was recommended to follow-up with the pulmonologist but was lost to follow-up because of nonpulmonary and nonrheumatoid arthritis complications. Settings Ambulatory clinic pharmacy practice, Community pharmacy, Consultant pharmacy practice. Practice Considerations Drugs used to treat rheumatoid arthritis may produce pulmonary toxicity similar to what is seen with the disease itself. Drug therapy may require modification if identified as an offending agent causing pulmonary manifestations. If fibrosing interstitial lung disease develops, the addition of nintedanib may need to be considered. Conclusion In order for pharmacists to better assist providers and patients and improve therapeutic outcomes, it is important for pharmacists to understand that pulmonary manifestations are common in patients having rheumatoid arthritis as well as with drugs used to treat rheumatoid arthritis.

Download Full-text

Lung Function Testing On and Off Dopaminergic Medication in Parkinson's Disease Patients With and Without Dysphagia

Movement Disorders Clinical Practice ◽

10.1002/mdc3.12251 ◽

2015 ◽

Vol 3 (2) ◽

pp. 146-150 ◽

Cited By ~ 6

Author(s):

Tareq Sawan ◽

Mary Louise Harris ◽

Christopher Kobylecki ◽

Laura Baijens ◽

Michel van Hooren ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Lung Function ◽

Lung Function Testing ◽

Dopaminergic Medication ◽

Function Testing

Download Full-text

- Understanding Lung Function and Disease: Performing Accurate Lung Function Testing

Essential Knowledge and Skills for Healthcare Assistants ◽

10.1201/b16365-23 ◽

2017 ◽

pp. 126-135

Keyword(s):

Lung Function ◽

Lung Function Testing ◽

Function Testing

Download Full-text

A case of unexplained dyspnoea: when lung function testing matters!

Breathe ◽

10.1183/20734735.025018 ◽

2018 ◽

Vol 14 (4) ◽

pp. 325-332 ◽

Cited By ~ 2

Author(s):

Pierantonio Laveneziana ◽

Marie-Cécile Niérat ◽

Antonella LoMauro ◽

Andrea Aliverti

Keyword(s):

Lung Function ◽

Lung Function Testing ◽

Function Testing

Download Full-text

Pulmonary Manifestations of Rheumatoid Arthritis

The Senior Care Pharmacist ◽

10.4140/tcp.n.2021.97. ◽

2021 ◽

Vol 36 (2) ◽

pp. 97-103

Author(s):

Keith J. Christensen ◽

Mark A. Malesker ◽

Nikhil Jagan ◽

Douglas R Moore

Keyword(s):

Rheumatoid Arthritis ◽

Needle Biopsy ◽

Pulmonary Toxicity ◽

Pharmacy Practice ◽

Pulmonary Function Testing ◽

Therapeutic Outcomes ◽

Pulmonary Manifestations ◽

Lost To Follow Up ◽

Function Testing

OBJECTIVE: To describe the case of an 88-yearold male with rheumatoid arthritis who developed pulmonary manifestations. Treatment for his RA previously included various biologics, while at the time of pulmonary consultation included meloxicam, methotrexate, and abatacept. Following chest scans, bronchoscopy, needle biopsy, pulmonary function testing, and a thoracentesis, the diagnosis of pleural effusion and nodules associated with rheumatoid arthritis was determined. The patient was recommended to follow-up with the pulmonologist but was lost to follow-up because of nonpulmonary and nonrheumatoid arthritis complications.<BR/> SETTINGS: Ambulatory clinic pharmacy practice, Community pharmacy, Consultant pharmacy practice.<BR/> PRACTICE CONSIDERATIONS: Drugs used to treat rheumatoid arthritis may produce pulmonary toxicity similar to what is seen with the disease itself. Drug therapy may require modification if identified as an offending agent causing pulmonary manifestations. If fibrosing interstitial lung disease develops, the addition of nintedanib may need to be considered.<BR/> CONCLUSION: In order for pharmacists to better assist providers and patients and improve therapeutic outcomes, it is important for pharmacists to understand that pulmonary manifestations are common in patients having rheumatoid arthritis as well as with drugs used to treat rheumatoid arthritis.

Download Full-text